{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T09:23:25Z","timestamp":1763198605525,"version":"3.45.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s13555-025-01553-5","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T06:58:25Z","timestamp":1758956305000},"page":"3605-3613","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clascoterone Stability When Combined with Topical Acne Medications In Vitro"],"prefix":"10.1007","volume":"15","author":[{"given":"Zoe D.","family":"Draelos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew M.","family":"Draelos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kizito","family":"Kyeremateng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Squittieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,27]]},"reference":[{"issue":"4","key":"1553_CR1","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/bjd.20882","volume":"186","author":"H Chen","year":"2022","unstructured":"Chen H, Zhang TC, Yin XL, Man JY, Yang XR, Lu M. Magnitude and temporal trend of acne vulgaris burden in 204 countries and territories from 1990 to 2019: an analysis from the global burden of disease study 2019. Br J Dermatol. 2022;186(4):673\u201383.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1553_CR2","doi-asserted-by":"publisher","first-page":"1006.e1\u2013e30","DOI":"10.1016\/j.jaad.2023.12.017","volume":"90","author":"RV Reynolds","year":"2024","unstructured":"Reynolds RV, Yeung H, Cheng CE, et\u00a0al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024;90(5):1006.e1-e30.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1553_CR3","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2298878","volume":"35","author":"JQ Del Rosso","year":"2024","unstructured":"Del Rosso JQ, Kircik L. The cutaneous effects of androgens and androgen-mediated sebum production and their pathophysiologic and therapeutic importance in acne vulgaris. J Dermatolog Treat. 2024;35(1):2298878.","journal-title":"J Dermatolog Treat"},{"key":"1553_CR4","unstructured":"WINLEVI\u00ae (clascoterone cream 1%). Full Prescribing Information. Cranbury: Sun Pharmaceutical Industries, Inc.; 2022."},{"issue":"6","key":"1553_CR5","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/jamadermatol.2020.0465","volume":"156","author":"A Hebert","year":"2020","unstructured":"Hebert A, Thiboutot D, Stein Gold L, et\u00a0al. Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials. JAMA Dermatol. 2020;156(6):621\u201330.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1553_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jaad.2020.04.087","volume":"83","author":"L Eichenfield","year":"2020","unstructured":"Eichenfield L, Hebert A, Gold LS, et\u00a0al. Open-label, long-term extension study to evaluate the safety of clascoterone (CB-03-01) cream, 1% twice daily, in patients with acne vulgaris. J Am Acad Dermatol. 2020;83(2):477\u201385.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1553_CR7","first-page":"412","volume":"18","author":"C Rosette","year":"2019","unstructured":"Rosette C, Agan FJ, Mazzetti A, Moro L, Gerloni M. Cortexolone 17alpha-propionate (clascoterone) is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro. J Drugs Dermatol. 2019;18(5):412\u20138.","journal-title":"J Drugs Dermatol"},{"key":"1553_CR8","first-page":"163","volume":"8","author":"E Abd","year":"2016","unstructured":"Abd E, Yousef SA, Pastore MN, et\u00a0al. Skin models for the testing of transdermal drugs. Clin Pharmacol. 2016;8:163\u201376.","journal-title":"Clin Pharmacol"},{"issue":"1","key":"1553_CR9","doi-asserted-by":"publisher","first-page":"21192","DOI":"10.1038\/s41598-020-78292-4","volume":"10","author":"JE Neil","year":"2020","unstructured":"Neil JE, Brown MB, Williams AC. Human skin explant model for the investigation of topical therapeutics. Sci Rep. 2020;10(1):21192.","journal-title":"Sci Rep"},{"issue":"24","key":"1553_CR10","doi-asserted-by":"publisher","first-page":"17255","DOI":"10.3390\/ijms242417255","volume":"24","author":"EHC Wang","year":"2023","unstructured":"Wang EHC, Barresi-Thornton R, Chen LC, et\u00a0al. The development of human ex vivo models of inflammatory skin conditions. Int J Mol Sci. 2023;24(24):17255.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1553_CR11","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1208\/s12249-024-02887-7","volume":"25","author":"Y Yang","year":"2024","unstructured":"Yang Y, Wang J, Wanasathop A, et\u00a0al. Evaluation of in vitro skin permeation of clascoterone from clascoterone topical cream, 1% (w\/w). AAPS PharmSciTech. 2024;25(6):186.","journal-title":"AAPS PharmSciTech"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01553-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01553-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01553-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T09:22:07Z","timestamp":1763198527000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01553-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,27]]},"references-count":11,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1553"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01553-5","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"subject":[],"published":{"date-parts":[[2025,9,27]]},"assertion":[{"value":"15 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Zoe D. Draelos was an investigator on this study and received a grant from Sun Pharma. She is also an editorial board member of\n                      Dermatology and Therapy\n                      . Zoe D. Draelos was not involved in the selection of peer reviewers for the manuscript, nor in any of the subsequent editorial decisions. Matthew M. Draelos has no conflicts to disclose. Kizito Kyeremateng and Nicholas Squittieri are employees of Sun Pharmaceutical Industries, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethical approval was not required since no human samples were used.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}